Rani Therapeutics Holdings, Inc.(RANI)Earnings, Financials & Key RatiosRani Therapeutics Holdings, Inc. (RANI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's precarious liquidity profile, highlighted by a cash balance of only $9.6M against a recurring quarterly burn rate, suggests a high probability of future dilutive financing to sustain operations.
Rani Therapeutics Holdings, Inc. (RANI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Rani Therapeutics Holdings, Inc. (RANI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.04vs $0.06+33.3% | $2Mvs $1M+51.8% |
| Q2 2026 | Mar 26, 2026 | $0.07vs $0.03-133.3% | $1Mvs $5M-70.8% |
| Q4 2025 | Nov 6, 2025 | $0.12vs $0.09-33.3% | —vs $5M |
| Q3 2025 | Aug 7, 2025 | $0.18vs $0.19+5.3% | — |
Recent stock market news and headlines for Rani Therapeutics Holdings, Inc. (RANI)
SAN JOSE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics”; “Rani” or the “Company”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the appointment of Nicholas Maestas as Chief Financial Officer, effective immediately.
Key metrics vs top competitors for Rani Therapeutics Holdings, Inc. (RANI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.71 | $46.33M | -1.58 | 58.85% | -1817.09% | -131.87% | — | |
| $103.41 | $6.73B | 30.33 | 0.5% | 18.05% | 24.33% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $27.67 | $3.46B | -212.85 | 91.34% | -0.57% | -1.41% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $221.38 | $6.96B | -8.28 | -94.52% | — | -43.74% | — |
Rani Therapeutics Holdings, Inc. (RANI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Rani Therapeutics Holdings, Inc. (RANI) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 27, 2026·SEC
May 15, 2026·SEC
Mar 26, 2026·SEC
Get notified when RANI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Rani Therapeutics Holdings, Inc. (RANI) stock FAQ — growth, dividends, profitability & financials explained
Rani Therapeutics Holdings, Inc. (RANI) reported $3.2M in revenue for fiscal year 2025. This represents a 224% increase from $1.0M in 2019.
Rani Therapeutics Holdings, Inc. (RANI) grew revenue by 58.9% over the past year. This is strong growth.
Rani Therapeutics Holdings, Inc. (RANI) reported a net loss of $29.4M for fiscal year 2025.
Rani Therapeutics Holdings, Inc. (RANI) has a return on equity (ROE) of -131.9%. Negative ROE indicates the company is unprofitable.
Rani Therapeutics Holdings, Inc. (RANI) had negative free cash flow of $17.1M in fiscal year 2025, likely due to heavy capital investments.
